RCUS (Arcus Biosciences) Total Equity: $524.0 Mil (As of Mar. 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $31.00
GF Value $13.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Total Equity?

Arcus Biosciences RCUS +2.48% 46 Total Equity is $524.0 Mil as of Mar. 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Arcus Biosciences's total equity for the quarter that ended in Mar. 2026 was $524.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Arcus Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Arcus Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcus Biosciences Total Equity Chart

Arcus Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 842.00 657.00 462.00 485.00 631.00

Arcus Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 531.00 549.00 436.00 631.00 524.00
RCUS
46GF Score
Arcus Biosciences Inc RCUS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcus Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Arcus Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1139-508
=631.0

Arcus Biosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=997-473
=524.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $524.0 Mil mean?
Arcus Biosciences (RCUS) has a Total Equity of $524.0 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Arcus Biosciences and its competitors.
Is Arcus Biosciences' Total Equity too high?
Arcus Biosciences' current Total Equity is $524.0 Mil. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Total Equity compare to TNGX and DYN?
Arcus Biosciences' Total Equity of $524.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Arcus Biosciences and its competitors. Arcus Biosciences's current Total Equity is $524.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.00 — trading 125.3% above its estimated fair value. The current Total Equity is $524.0 Mil. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Total Equity is $524.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $31.00 is trading 125.3% above its estimated GF Value™ of $13.76. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Total Equity: $524.0 Mil
  • GF Value™: $13.76 vs. price of $31.00 (125.3% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.00
Price
$13.76
GF Value